Filing Details

Accession Number:
0001735276-21-000020
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-02-26 16:03:20
Reporting Period:
2021-02-24
Accepted Time:
2021-02-26 16:03:20
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1178670 Alnylam Pharmaceuticals Inc. ALNY Pharmaceutical Preparations (2834) 770602661
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1180432 John Maraganore 675 West Kendall Street
Henri A. Termeer Square
Cambridge MA 02142
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-02-25 33,979 $7.10 240,015 No 4 M Direct
Common Stock Disposition 2021-02-25 1,001 $143.88 239,014 No 4 S Direct
Common Stock Disposition 2021-02-25 6,129 $145.15 232,885 No 4 S Direct
Common Stock Disposition 2021-02-25 9,376 $146.13 223,509 No 4 S Direct
Common Stock Disposition 2021-02-25 6,097 $146.98 217,412 No 4 S Direct
Common Stock Disposition 2021-02-25 4,375 $148.00 213,037 No 4 S Direct
Common Stock Disposition 2021-02-25 1,364 $148.96 211,673 No 4 S Direct
Common Stock Disposition 2021-02-25 2,054 $150.22 209,619 No 4 S Direct
Common Stock Disposition 2021-02-25 1,415 $151.31 208,204 No 4 S Direct
Common Stock Disposition 2021-02-25 1,138 $152.46 207,066 No 4 S Direct
Common Stock Disposition 2021-02-25 431 $153.33 206,635 No 4 S Direct
Common Stock Disposition 2021-02-25 599 $154.59 206,036 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Acquisiton 2021-02-24 79,998 $0.00 79,998 $151.59
Common Stock Stock Option (right to buy) Disposition 2021-02-25 33,979 $0.00 33,979 $7.10
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
79,998 2031-02-23 No 4 A Direct
101,936 2021-11-30 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 3,133 Indirect by Managed Account
Footnotes
  1. All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,979 options exercised and sold by the reporting person were due to expire on November 30, 2021.
  2. Sale prices ranged from $143.50 to $144.43.
  3. Sale prices ranged from $144.54 to $145.54.
  4. Sale prices ranged from $145.55 to $146.55.
  5. Sale prices ranged from $146.59 to $147.59.
  6. Sale prices ranged from $147.60 to $148.59.
  7. Sale prices ranged from $148.66 to $149.65.
  8. Sale prices ranged from $149.73 to $150.62.
  9. Sale prices ranged from $150.88 to $151.68.
  10. Sale prices ranged from $151.92 to $152.76.
  11. Sale prices ranged from $153.05 to $153.90.
  12. Sale prices ranged from $154.37 to $154.68.
  13. Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
  14. Represents the time-vested stock option portion of the reporting person's Annual Equity Award for 2020. The reporting person also received 42,879 performance stock units that will vest upon the achievement of four specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the performance stock units vest.
  15. The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.
  16. The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.